Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Mar;65(2):127–137. doi: 10.1016/S0011-393X(04)90025-2

Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study

Oguz Ozcelik 1,∗, Halil Dogan 2, Haluk Kelestimur 1
PMCID: PMC4053149  PMID: 24936112

Abstract

Background: Leptin, which has been identified as an antiobesity hormone, regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis. It appears that leptin may be an important factor in obesity management. Orlistat, a pancreatic lipase inhibitor, could reduce fat absorption and promote weight loss due to leptin metabolism.

Objective: The purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels.

Methods: Obese women (body mass index [BMI], 30 kg/m2) aged 18 to 50 years were randomly assigned to receive 12 weeks of oral treatment with diet-orlistat (120 mg TID) (DO group) or diet-placebo (DP group). During the treatment period, patients were asked to eat a balanced diet of -1200 to 1600 kcal/d. Body composition was determined by bioelectrical impedance. Serum leptin levels were measured using radioimmunoassay at baseline and at study end.

Results: A total of 24 patients entered the study; 14 patients (mean [SE] BMI, 37.7 [1.1] kg/m2) received orlistat and 10 patients (mean [SE] BMI, 39.4 [1.3] kg/m2) received placebo. Compared with baseline, mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group (9.1% and 14.8%, respectively; both P = 0.001) and in the DP group (9.5% and 17.6%; both P = 0.005). The between-group differences were not statistically significant. Mean (SE) serum leptin levels also decreased significantly after treatment in the DO group (16.2 [1.2] vs 9.0 [1.0] ng/mL; P = 0.001) and in the DP group (19.3 [2.1] vs 9.7 [1.4] ng/mL; P = 0.005). The between-group difference was not statistically significant.

Conclusions: In this study of obese women, orlistat treatment was associated with a similar decrease in body weight, fat mass, and serum leptin levels as placebo over a 12-week period. In this regard, short-term orlistat therapy may not provide an additional effect on serum leptin levels, and reduction in leptin levels were closely related to the decrease in fat mass.

Keywords: leptin, obesity, orlistat, pharmacotherapy

Full Text

The Full Text of this article is available as a PDF (201.6 KB).

References

  • 1.Pi-Sunyer F.X. Medical hazards of obesity. Ann Intern Med. 1993;119:655–660. doi: 10.7326/0003-4819-119-7_part_2-199310011-00006. [DOI] [PubMed] [Google Scholar]
  • 2.Kannel W.B., D'Agostino R.B., Cobb J.L. Effects of weight on cardiovascular disease. Am J Clin Nutr. 1996;63:S419–S422. doi: 10.1093/ajcn/87.6.1602. (Suppl) [DOI] [PubMed] [Google Scholar]
  • 3.Doucet E., Tremblay A. Food intake, energy balance and body weight control. Eur J Clin Nutr. 1997;51:846–855. doi: 10.1038/sj.ejcn.1600497. [DOI] [PubMed] [Google Scholar]
  • 4.Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci. 2002;967:379–388. doi: 10.1111/j.1749-6632.2002.tb04293.x. [DOI] [PubMed] [Google Scholar]
  • 5.Frederich C., Hamann A., Anderson S. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action. Nat Med. 1995;1:1311–1314. doi: 10.1038/nm1295-1311. [DOI] [PubMed] [Google Scholar]
  • 6.Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002;60:S1–S14. doi: 10.1301/002966402320634878. [DOI] [PubMed] [Google Scholar]
  • 7.Hamilton B.S., Paglia D., Kwan A.Y., Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med. 1995;1:953–956. doi: 10.1038/nm0995-953. [DOI] [PubMed] [Google Scholar]
  • 8.Considine R.V., Sinha M.K., Heiman M.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–295. doi: 10.1056/NEJM199602013340503. [DOI] [PubMed] [Google Scholar]
  • 9.Grinspoon S., Gulick T., Askari H. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab. 1996;81:3861–3863. doi: 10.1210/jcem.81.11.8923829. [DOI] [PubMed] [Google Scholar]
  • 10.Ferron F., Considine R.V., Peino R. Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non-specific eating disorders correlate with the body mass index but are independent of the respective disease. Clin Endocrinol (Oxf) 1997;46:289–293. doi: 10.1046/j.1365-2265.1997.1260938.x. [DOI] [PubMed] [Google Scholar]
  • 11.Saladin R., De Vos P., Guerre-Millo M. Transient increase in obese gene expression after food intake or insulin administration. Nature. 1995;377:527–529. doi: 10.1038/377527a0. [DOI] [PubMed] [Google Scholar]
  • 12.Kolaczynski J.W., Ohannesian J.P., Considine R.V. Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab. 1996;81:4162–4165. doi: 10.1210/jcem.81.11.8923877. [DOI] [PubMed] [Google Scholar]
  • 13.Racette S.B., Coppack S.W., Landt M., Klein S. Leptin production during moderateintensity aerobic exercise. J Clin Endocrinol Metab. 1997;82:2275–2277. doi: 10.1210/jcem.82.7.4037. [DOI] [PubMed] [Google Scholar]
  • 14.Pérusse L., Collier G., Gagnon J. Acute and chronic effects of exercise on leptin levels in humans. J Appl Physiol. 1997;83:5–10. doi: 10.1152/jappl.1997.83.1.5. [DOI] [PubMed] [Google Scholar]
  • 15.Hulver M.W., Houmard J.A. Plasma leptin and exercise: Recent findings. Sports Med. 2003;33:473–482. doi: 10.2165/00007256-200333070-00001. [DOI] [PubMed] [Google Scholar]
  • 16.Krempf M., Louvet J.-P., Allanic H. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord. 2003;27:591–597. doi: 10.1038/sj.ijo.0802281. [DOI] [PubMed] [Google Scholar]
  • 17.Van Gaal L.F., Broom J.I., Enzi G., Toplak H, Orlistat Dose-Ranging Study Group Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month doseranging study. Eur J Clin Pharmacol. 1998;54:125–132. doi: 10.1007/s002280050433. [DOI] [PubMed] [Google Scholar]
  • 18.Deurenberg P. Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity. Am J Clin Nutr. 1996;64:S449–S452. doi: 10.1093/ajcn/64.3.449S. (Suppl) [DOI] [PubMed] [Google Scholar]
  • 19.Utter A.C., Nieman D.C., Ward A.N., Butterworth D.E. Use of the leg-to-leg bioelectrical impedance method in assessing body-composition change in obese women. Am J Clin Nutr. 1999;69:603–607. doi: 10.1093/ajcn/69.4.603. [DOI] [PubMed] [Google Scholar]
  • 20.Sinha M.K., Ohannesian J.P., Heiman M.L. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 1996;97:1344–1347. doi: 10.1172/JCI118551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Davidson M.H., Hauptman J., DiGirolamo M. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA. 1999;281:235–242. doi: 10.1001/jama.281.3.235. [DOI] [PubMed] [Google Scholar]
  • 22.Hassink S.G., Sheslow D.V., de Lancey E. Serum leptin in children with obesity: Relationship to gender and development. Pediatrics. 1996;98:201–203. [PubMed] [Google Scholar]
  • 23.Haffner S.M., Gingerich R.L., Miettinen H., Stern M.P. Leptin concentrations in relation to overall adiposity and regional body fat distribution in Mexican Americans. Int J Obes Relat Metab Disord. 1996;20:904–908. [PubMed] [Google Scholar]
  • 24.Harris R.B.S., Bowen H.M., Mitchell T.D. Leptin resistance in mice is determined by gender and duration of exposure to high-fat diet. Physiol Behav. 2003;78:543–555. doi: 10.1016/s0031-9384(03)00035-0. [DOI] [PubMed] [Google Scholar]
  • 25.Klein S., Coppack S.W., Mohamed-Ali V., Landt M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes. 1996;45:984–987. doi: 10.2337/diab.45.7.984. [DOI] [PubMed] [Google Scholar]
  • 26.Pilcova R., Sulcova J., Hill M. Leptin levels in obese children: Effects of gender, weight reduction and androgens. Physiol Res. 2003;52:53–60. [PubMed] [Google Scholar]
  • 27.Doucet E., St--Pierre S., Alméras N., Quebec Family Study Group Fasting insulin levels influence plasma leptin levels independently from the contribution of adiposity: Evidence from both a cross-sectional and an intervention study. J Clin Endocrinol Metab. 2000;85:4231–4237. doi: 10.1210/jcem.85.11.6980. [DOI] [PubMed] [Google Scholar]
  • 28.Rodrigues A.M., Radominski R.B., Suplicy H.L. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab. 2002;87:1621–1626. doi: 10.1210/jcem.87.4.8420. [DOI] [PubMed] [Google Scholar]
  • 29.Rosenbaum M., Nicolson M., Hirsch J. Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab. 1997;82:3647–3654. doi: 10.1210/jcem.82.11.4390. [DOI] [PubMed] [Google Scholar]
  • 30.Lerario D.D., Ferreira S.R., Miranda W.L., Chacra A.R. Influence of dexamethasone and weight loss on the regulation of serum leptin levels in obese individuals. Braz JMed Biol Res. 2001;34:479–487. doi: 10.1590/s0100-879x2001000400007. [DOI] [PubMed] [Google Scholar]
  • 31.Wadden T.A., Considine R.V., Foster G.D. Short- and long-term changes in serum leptin in dieting obese women: Effects of caloric restriction and weight loss. J Clin Endocrinol Metab. 1998;83:214–218. doi: 10.1210/jcem.83.1.4494. [DOI] [PubMed] [Google Scholar]
  • 32.Koutsari C., Karpe F., Humphreys S.M. Plasma leptin is influenced by diet composition and exercise. Int J Obes Relat Metab Disord. 2003;27:901–906. doi: 10.1038/sj.ijo.0802322. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES